Boehringer Ingelheim Head Advises India Generics To Focus On R&D
This article was originally published in PharmAsia News
Executive Summary
The chairman of Boehringer Ingelheim says India's makers of generic drugs need to invest in research if they want to effect changes in the nation's patent-protection policy and development.